Fox Chase Cancer Center News

PHILADELPHIA (February 25, 2020) – Vladimir Kolenko, MD, PhD, received the two-year $200,000 NCI grant to target cholesterol homeostasis using genetic and pharmacological approaches in order to reinstate or re-emphasize sensitivity of prostate cancer cells to anti-androgens like abiraterone and enzalutamide.

PHILADELPHIA (February 20, 2020) – Neal S. Topham, MD, FACS, researched the use of a new resorbable mesh to minimize the risk of hernias and bulges after bilateral flap breast reconstruction.

PHILADELPHIA (February 19, 2020) – Edna Cukierman and Igor Astsaturov were among a group of almost 30 experts convened to discuss the current understanding of CAFs.

PHILADELPHIA (February 18, 2020) – In a study published today, researchers at Fox Chase Cancer Center have identified a new kinase target for the treatment of high-grade serous ovarian cancer that has the potential to lead to the development of new drugs.

PHILADELPHIA (February 14, 2020) – Dr. Cukierman's induction as a fellow is notable because historically AGA has been a medical association. Cukierman is not a medical doctor, but she joined AGA in order to better understand the medical side of gastroenterology.

PHILADELPHIA (February 13, 2020) – A research article featuring featured Fox Chase Cancer Center  was awarded the 2019 Journal of Oncology Practice (JOP) Editor’s Pick Award for being one of the top five most-read articles published in JOP in 2019.

PHILADELPHIA (February 10, 2020)—Its involvement in causing over 50 percent of all cancers makes p53 one of the most well-known cancer genes. But there are some malignancies, like kidney cancer, that rarely have p53 mutations.

PHILADELPHIA (February 5, 2020) –Roland L. Dunbrack Jr., PhD, director of the Molecular Modeling Facility at Fox Chase Cancer Center, and his team have updated their Protein Common Interface Database (ProtCID) to include data on the individual domain level, which greatly increases the number of large protein-protein clusters available in the database.